Bone Biologics appoints Phillip Meikle to board, replacing retiring director Don Hankey

Bone Biologics Corp

Phillip Meikle appointed to Bone Biologics board effective October 16, 2024.
Meikle founded Biosystems of New England (sold to Stryker in 2019), 30+ years orthopedic/spine experience.
Don R. Hankey retired from board after seven years of service; board size stays at four.
Meikle will be compensated in the same manner as other Bone Biologics directors.
No arrangements or transactions requiring disclosure under Item 404(a) were identified.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Phillip Meikle

Director

BBLG · Bone Biologics Corp

Effective: 2024-10-16
Filed: October 21, 2024, 7:59 PM ET

On October 16, 2024, the Board of Directors (the “Board”) of Bone Biologics Corporation (the “Company”) appointed Phillip Meikle to the Company’s Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Phillip Meikle was appointed as Director at Bone Biologics Corp.

Action: appointed
Role: Director

Exact text from the filing

On October 16, 2024, the Board of Directors (the “Board”) of Bone Biologics Corporation (the “Company”) appointed Phillip Meikle to the Company’s Board.

View on SEC.gov

Bone Biologics Corp filing history →

Source: SEC EDGAR

accession 0001493152-24-041710

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.